Innate Pharma (IPH) — Long-term Investment Intensity
Innate Pharma (IPH) has a Long-term Investment Intensity of 16.7% as of December 2025. Long-term investments of €10.46 Million represent 16.7% of total assets of €62.72 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Check how aggressively does Innate Pharma reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
LT Investment Intensity
Long-term Investments
Total Assets
Country
Innate Pharma Long-term Investment Intensity (2013–2025)
This chart shows how Innate Pharma's Long-term Investment Intensity has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the intensity stands at 16.7%, reflecting long-term investments of €10.46 Million against total assets of €62.72 Million EUR. Explore IPH debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for Innate Pharma (2013–2025)
The table below presents the year-by-year Long-term Investment Intensity for Innate Pharma from 2013 to 2025, covering 13 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see IPH company net worth.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 16.7% | €10.46 Million | €62.72 Million | ▲ +7.4 pp |
| 2024 | 9.3% | €10.28 Million | €111.06 Million | ▲ +3.9 pp |
| 2023 | 5.3% | €9.80 Million | €184.19 Million | ▼ -11.6 pp |
| 2022 | 16.9% | €35.12 Million | €207.86 Million | ▲ +2.0 pp |
| 2021 | 14.9% | €39.88 Million | €267.50 Million | ▲ +2.2 pp |
| 2020 | 12.7% | €38.93 Million | €307.42 Million | ▲ +3.4 pp |
| 2019 | 9.2% | €37.01 Million | €401.36 Million | ▲ +1.4 pp |
| 2018 | 7.8% | €35.18 Million | €451.22 Million | ▼ -15.9 pp |
| 2017 | 23.7% | €60.47 Million | €255.02 Million | ▲ +12.0 pp |
| 2016 | 11.7% | €32.98 Million | €281.58 Million | ▲ +0.8 pp |
| 2015 | 10.9% | €33.24 Million | €305.96 Million | ▲ +10.8 pp |
| 2014 | 0.1% | €84.00K | €90.69 Million | ▼ -0.4 pp |
| 2013 | 0.5% | €272.00K | €55.88 Million | — |